Indonesia first to green light Novavax COVID-19 vaccine
Biotechnology company Novavax says that Indonesia has given the world’s first emergency use authorization for its COVID-19 vaccine, which uses a different technology than current shots
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Biotechnology company Novavax said Monday that Indonesia has given the world's first emergency use authorization for its COVID-19 vaccine, which uses a different technology than current shots.
The vaccine doesn't require the extremely cold storage temperatures that some other vaccines need, which could allow it to play an important role in boosting supplies in poorer countries around the world.
The two-dose Novavax vaccine is made with lab-grown copies of the spike protein that coats the coronavirus. That’s very different from widely used mRNA vaccines such as Pfizer and Moderna that deliver genetic instructions for the body to make its own spike protein.
The emergency authorization of the vaccine is a “very important step” for Indonesia's COVID-19 vaccination program, Indonesian epidemiologist Dicky Budiman said.
“This vaccine will be much easier to transport, store and distribute in a place like Indonesia, where we have many islands,” he said.
Budiman said if the rollout of the vaccine is successful, it could lead to its approval and use in other developing nations.
The need for more vaccines remains critical in many countries, including Indonesia.
In June, U.S.-based Novavax announced the vaccine had proven about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the U.S. and Mexico It also worked against variants circulating in those countries at the time, it said.
The company said side effects were mild and included tenderness at the injection site, headache, aches and pains and fatigue.
In October, it addressed concerns that production of the vaccine had been slowed due to a lack of raw materials and other issues, saying it planned to “achieve a capacity of 150 million doses per month by the end of the fourth quarter” through partnerships with Serum Institute of India SK Bioscience in South Korea and Takeda in Japan, among others.
Novavax said it has already filed for authorization of the vaccine in the United Kingdom, European Union, Canada, Australia, India and the Philippines.
Indonesia was battered by a deadly wave of COVID-19 fueled by the delta variant and post-holiday travel from June through August. New cases have now dropped, averaging less than 1,000 a day since mid October.
About 36% of people in Indonesian have received two doses of a vaccine, and about 58% have received one dose, according to the Ministry of Health.
Over 143,400 people have died from the virus in Indonesia. The number is thought to be an undercount due to low testing and tracing.
___
Associated Press writer Niniek Karmini contributed to this report.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.